MedPath

Evaluation of the clinical efficacy of Shenshuaining capsule in the treatment of end-stage renal disease with peritoneal dialysis

Phase 1
Recruiting
Conditions
end-stage renal disease
Registration Number
ITMCTR1900002792
Lead Sponsor
The First Affiliated Hospital of Chengdu Medical College
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Aged over 18 years male and female;
2. Clear consciousness;
3. Regular peritoneal dialysis was performed and the urine volume was > 100ml at 24 hours;
4. Patients with stable condition who insist on regular review of relevant indicators every 3 months;
5. Volunteer to participate in this study and sign the informed consent;
6. Chinese medicine dialectic is the spleen of the spleen or the spleen and blood bruising.

Exclusion Criteria

1. Allergic constitution or allergic to a variety of drugs;
2. There are serious digestive tract diseases that affect drug absorption,such as active ulcer,Chronic diarrhea,etc.;
3. A woman who is pregnant or breast-feeding;
4. Inability to cooperate, as with a psychopath;
5. Alcohol or drug abusers;
6. Patients who had been given Niaoduqing Particles before enrollment;
7. Drugs containing rhubarb were used before enrollment or during the trial.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum phosphorus;Parathyroid hormone;
Secondary Outcome Measures
NameTimeMethod
ß2 microglobulin;hemoglobin;C-reactive protein;blood urea nitrogen;Serum calcium;ferritin;Transferrin saturation;creatinine;
© Copyright 2025. All Rights Reserved by MedPath